Schlieren, Switzerland – July 6, 2020 InSphero AG, the pioneer of 3D cell-based assay technology, today announced that the company is launching an online R&D Solutions Store to provide a convenient, easy way to order its flagship, assay-ready 3D InSight™ Human Liver Microtissues, long recognized as the industry gold standard for compound screening and drug risk assessment. Researchers can now purchase everything needed to get started testing compounds at the bench using highly standardized, physiological 3D liver models – with only a few clicks and a credit card. To further help support laboratories reopening after the extended COVID-19 shutdown, InSphero is offering free shipping to Europe and North America for first time orders placed on the online store through September 30, 2020.
For its initial online store offering, InSphero is bundling together Akura™ 96 plates of 3D InSight™ Human Liver Microtissues (multi-donor hepatocytes in co-culture with Kupffer cells and liver endothelial cells) with 3D InSight™ Human Liver Maintenance Media. The cost of a plate of human liver microtissues is roughly equivalent to that of a frozen vial of hepatocytes and Kupffer cells.
“When we first founded InSphero back in 2009, one of my personal goals was to make our transformative 3D microtissue technology more accessible and affordable for the greater research community,“ says InSphero CEO and co-founder Jan Lichtenberg, PhD. “With the combination of our competitive pricing, unrivalled biological functionality and uniformity, and now the convenience of online ordering with popular secure payment methods, we are opening the door for academics and smaller biotech companies to access our technology which is already in use by many top pharma companies worldwide.“
For more information about 3D InSight™ Human Liver Microtissues or to place an order online, visit https://shop.insphero.com.
InSphero Contact
Dr. Frank Junker
Chief Business Officer
Phone +41 44 5150490
About InSphero
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
Learn more at www.insphero.com and follow us on Twitter and LinkedIn.